Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to transform oncology drug development, has entered into a definitive agreement for a registered direct offering expected to raise approximately $4 million in gross proceeds. The company will sell 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share. In a concurrent private placement, Lantern will issue unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share, potentially generating another $4 million in gross proceeds if fully exercised for cash.
The offering is expected to close on or about September 30, 2026, subject to customary closing conditions. Rodman & Renshaw LLC is acting as the exclusive placement agent. Lantern Pharma intends to use the net proceeds for working capital and other general corporate purposes. The unregistered warrants will become exercisable only upon stockholder approval and will expire five years following that approval. For full details, see the company's official press release.
This capital infusion matters because it provides Lantern Pharma with additional financial flexibility as it advances its pipeline of AI-driven oncology therapies. The company's proprietary RADR artificial intelligence and machine-learning platform integrates large-scale genomic and biological data to identify patients most likely to benefit from its therapies and to guide biomarker-driven clinical development. Lantern's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The proceeds will support ongoing research and development, potentially accelerating the path to clinical milestones.
For investors, the offering signals continued commitment to funding innovation in a capital-intensive sector. The dual structure of the offering—immediate shares plus warrants—offers the company a mechanism to raise additional capital if the stock performs well, while minimizing immediate dilution. However, the warrants are subject to stockholder approval, adding a layer of uncertainty. The news comes amid heightened interest in AI applications in drug discovery, where Lantern Pharma aims to reduce the cost, pace, and precision challenges of oncology drug development.
InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication, distributed the announcement. InvestorWire is part of a Dynamic Brand Portfolio within IBN, offering access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. The syndication helps ensure that news like Lantern Pharma's offering reaches a wide audience of investors, influencers, and journalists.
